Hematogenix MRD Assay Supports FDA Approval of Bristol Myers Squibb's New Multiple Myeloma Therapy
Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA approval of ZENBEXUS™, the first approved CELMoD therapy for Multiple Myeloma.
Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay was instrumental in the U.S. Food and Drug Administration's (FDA) approval process for Bristol Myers Squibb's new Multiple Myeloma therapy, ZENBEXUS™ (iberdomide).
ZENBEXUS™ marks the first approved CELMoD (cereblon E3 ligase modulator) therapy on the market, and Hematogenix's assay measured its primary efficacy endpoint. This approval reinforces Hematogenix's role in supporting oncology registrational trials.
Measuring MRD levels is increasingly important in oncology for assessing treatment response and monitoring patient prognosis. Hematogenix's technology provides a sensitive and specific method for detecting minimal residual disease, crucial for the development and approval of new cancer treatments.
The FDA's clearance of Bristol Myers Squibb's ZENBEXUS™ offers a new therapeutic option for patients diagnosed with Multiple Myeloma. Hematogenix continues to provide specialized diagnostic solutions for the field of oncology research.